FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978372990> ?p ?o ?g. }

• W1978372990 endingPage "B11" @default.
• W1978372990 startingPage "B11" @default.
• W1978372990 abstract "Abstract Introduction: JI-101 is a highly selective and potent angiogenesis inhibitor with unique EphB4 activity that distinguishes it from other agents in clinical development. We report the preclinical pharmacology and early clinical experience with this compound. Procedures: Lead optimization was used to identify cgi1842 (now JI-101) with a targeted activity profile that is selective and unique. JI-101 was tested in binding, enzymatic, and cell-based assays for activity against kinase and non-kinase targets. Preclinical in vivo testing for PK, PD, efficacy, and safety pharmacology was performed in mouse, rat, guinea pig, and dog. A Phase I clinical trial is underway: 9 patients, 3/cohort, are being treated with 28-day oral daily dosing at 100 mg, 200 mg, and 400 mg. PK, PD, and imaging analyses are being performed. Data: JI-101 has a MW of 466D and high (&lt;100 nm) potency against VEGFR2, EphB4, and PDGFR in enzymatic and cell-based assays. Broad kinase cross-screening (Ambit KinomeScan, 445 kinases) reveals that JI-101 is highly selective for angiogenic kinases with only 23 kinases demonstrating a Kd 15). JI-101 was co-administered with paclitaxel in a MDA-MB-231 mouse xenotransplant model, resulting in greater efficacy and no increased toxicity. Based on 28-day GLP toxicology studies conducted in rat and dog, a 100 mg qd starting dose (2 × 50 mg capsules) was chosen for Phase I studies. JI-101 appears to be very well-tolerated to date with no dose limiting toxicities. Patients have received 1–8 cycles and 5 remain on study at 100 mg (1 pt), 200 mg (1 pt), and 400 mg (3 pt). Manageable hypertension has been seen in all cohorts indicating a possible PD effect. Further clinical details of the PK, PD, tolerability and efficacy of JI-101 will be presented. Conclusions: JI-101 potently inhibits 3 critical angiogenic kinases (VEGFR2, EphB4, and PDGFR) and is the only such “triple” angiogenesis inhibitor currently in development. JI-101 shows robust preclinical and clinical pharmacology and is well-tolerated to date in human trials. In tumors where EphB4 may play an oncogenic role, such as head and neck cancer, JI-101 may have anti-proliferative effects in addition to anti-angiogenic effects and should be amenable to combination therapy. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B11." @default.
• W1978372990 created "2016-06-24" @default.
• W1978372990 creator A5002863138 @default.
• W1978372990 creator A5008125124 @default.
• W1978372990 creator A5031415255 @default.
• W1978372990 creator A5037114287 @default.
• W1978372990 creator A5040416930 @default.
• W1978372990 creator A5050840284 @default.
• W1978372990 creator A5051908824 @default.
• W1978372990 creator A5061012285 @default.
• W1978372990 creator A5061144030 @default.
• W1978372990 creator A5061499576 @default.
• W1978372990 creator A5062691463 @default.
• W1978372990 creator A5069690249 @default.
• W1978372990 creator A5075218449 @default.
• W1978372990 creator A5081412933 @default.
• W1978372990 date "2009-12-01" @default.
• W1978372990 modified "2023-10-12" @default.
• W1978372990 title "Abstract B11: Preclinical and preliminary phase 1 trial results of JI-101: A novel, oral tyrosine kinase inhibitor that selectively targets VEGFR2, EphB4, and PDGFR" @default.
• W1978372990 doi "https://doi.org/10.1158/1535-7163.targ-09-b11" @default.
• W1978372990 hasPublicationYear "2009" @default.
• W1978372990 type Work @default.
• W1978372990 sameAs 1978372990 @default.
• W1978372990 citedByCount "6" @default.
• W1978372990 countsByYear W19783729902012 @default.
• W1978372990 countsByYear W19783729902015 @default.
• W1978372990 crossrefType "journal-article" @default.
• W1978372990 hasAuthorship W1978372990A5002863138 @default.
• W1978372990 hasAuthorship W1978372990A5008125124 @default.
• W1978372990 hasAuthorship W1978372990A5031415255 @default.
• W1978372990 hasAuthorship W1978372990A5037114287 @default.
• W1978372990 hasAuthorship W1978372990A5040416930 @default.
• W1978372990 hasAuthorship W1978372990A5050840284 @default.
• W1978372990 hasAuthorship W1978372990A5051908824 @default.
• W1978372990 hasAuthorship W1978372990A5061012285 @default.
• W1978372990 hasAuthorship W1978372990A5061144030 @default.
• W1978372990 hasAuthorship W1978372990A5061499576 @default.
• W1978372990 hasAuthorship W1978372990A5062691463 @default.
• W1978372990 hasAuthorship W1978372990A5069690249 @default.
• W1978372990 hasAuthorship W1978372990A5075218449 @default.
• W1978372990 hasAuthorship W1978372990A5081412933 @default.
• W1978372990 hasConcept C112705442 @default.
• W1978372990 hasConcept C121608353 @default.
• W1978372990 hasConcept C126322002 @default.
• W1978372990 hasConcept C150903083 @default.
• W1978372990 hasConcept C170493617 @default.
• W1978372990 hasConcept C184235292 @default.
• W1978372990 hasConcept C185592680 @default.
• W1978372990 hasConcept C202751555 @default.
• W1978372990 hasConcept C207001950 @default.
• W1978372990 hasConcept C26291073 @default.
• W1978372990 hasConcept C2776190711 @default.
• W1978372990 hasConcept C2777288759 @default.
• W1978372990 hasConcept C2778820342 @default.
• W1978372990 hasConcept C2780035454 @default.
• W1978372990 hasConcept C2780394083 @default.
• W1978372990 hasConcept C29730261 @default.
• W1978372990 hasConcept C42362537 @default.
• W1978372990 hasConcept C502942594 @default.
• W1978372990 hasConcept C55493867 @default.
• W1978372990 hasConcept C57992300 @default.
• W1978372990 hasConcept C71924100 @default.
• W1978372990 hasConcept C86803240 @default.
• W1978372990 hasConcept C98274493 @default.
• W1978372990 hasConceptScore W1978372990C112705442 @default.
• W1978372990 hasConceptScore W1978372990C121608353 @default.
• W1978372990 hasConceptScore W1978372990C126322002 @default.
• W1978372990 hasConceptScore W1978372990C150903083 @default.
• W1978372990 hasConceptScore W1978372990C170493617 @default.
• W1978372990 hasConceptScore W1978372990C184235292 @default.
• W1978372990 hasConceptScore W1978372990C185592680 @default.
• W1978372990 hasConceptScore W1978372990C202751555 @default.
• W1978372990 hasConceptScore W1978372990C207001950 @default.
• W1978372990 hasConceptScore W1978372990C26291073 @default.
• W1978372990 hasConceptScore W1978372990C2776190711 @default.
• W1978372990 hasConceptScore W1978372990C2777288759 @default.
• W1978372990 hasConceptScore W1978372990C2778820342 @default.
• W1978372990 hasConceptScore W1978372990C2780035454 @default.
• W1978372990 hasConceptScore W1978372990C2780394083 @default.
• W1978372990 hasConceptScore W1978372990C29730261 @default.
• W1978372990 hasConceptScore W1978372990C42362537 @default.
• W1978372990 hasConceptScore W1978372990C502942594 @default.
• W1978372990 hasConceptScore W1978372990C55493867 @default.
• W1978372990 hasConceptScore W1978372990C57992300 @default.
• W1978372990 hasConceptScore W1978372990C71924100 @default.
• W1978372990 hasConceptScore W1978372990C86803240 @default.
• W1978372990 hasConceptScore W1978372990C98274493 @default.
• W1978372990 hasIssue "12_Supplement" @default.
• W1978372990 hasLocation W19783729901 @default.
• W1978372990 hasOpenAccess W1978372990 @default.
• W1978372990 hasPrimaryLocation W19783729901 @default.
• W1978372990 hasRelatedWork W1969154832 @default.
• W1978372990 hasRelatedWork W2050873057 @default.
• W1978372990 hasRelatedWork W2075312788 @default.
• W1978372990 hasRelatedWork W2155615242 @default.
• W1978372990 hasRelatedWork W2512058705 @default.
• W1978372990 hasRelatedWork W2908272576 @default.
• W1978372990 hasRelatedWork W3008063389 @default.

• next